Circulating Th17, Th22, and Th1 cells are increased in psoriasis.

[1]  V. Kuchroo,et al.  Interleukin-17 and type 17 helper T cells. , 2009, The New England journal of medicine.

[2]  Andrew Blauvelt,et al.  Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. , 2009, The Journal of investigative dermatology.

[3]  H. Spits,et al.  Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells , 2009, Nature Immunology.

[4]  D. Jarrossay,et al.  Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells , 2009, Nature Immunology.

[5]  Lisa C. Zaba,et al.  IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. , 2009, The Journal of allergy and clinical immunology.

[6]  Changyou Wu,et al.  Memory IL‐22‐producing CD4+ T cells specific for Candida albicans are present in humans , 2009, European journal of immunology.

[7]  J. Goodall,et al.  Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[8]  J. Pober,et al.  Interleukin-17 and Interferon-γ Are Produced Concomitantly by Human Coronary Artery–Infiltrating T Cells and Act Synergistically on Vascular Smooth Muscle Cells , 2009, Circulation.

[9]  Erin E. Murphy,et al.  Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation , 2009, The Journal of experimental medicine.

[10]  E. Antiga,et al.  Serum Levels of IL-17 and IL-22 Are Reduced by Etanercept, but not by Acitretin, in Patients with Psoriasis: a Randomized-Controlled Trial , 2009, Journal of Clinical Immunology.

[11]  Pui-Yan Kwok,et al.  Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways , 2008, Nature Genetics.

[12]  James T. Elder,et al.  Induction of IL-17+ T Cell Trafficking and Development by IFN-γ: Mechanism and Pathological Relevance in Psoriasis1 , 2008, The Journal of Immunology.

[13]  L. Cosmi,et al.  Human interleukin 17–producing cells originate from a CD161+CD4+ T cell precursor , 2008, The Journal of experimental medicine.

[14]  S. Tangye,et al.  Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3 , 2008, The Journal of experimental medicine.

[15]  M. Lebwohl,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) , 2008, The Lancet.

[16]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[17]  Lisa C. Zaba,et al.  Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. , 2008, The Journal of investigative dermatology.

[18]  Yong Chen,et al.  The Th17/Treg imbalance in patients with acute coronary syndrome. , 2008, Clinical immunology.

[19]  A. Kimball,et al.  Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. , 2008, Archives of dermatology.

[20]  Lisa C. Zaba,et al.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses , 2007, The Journal of experimental medicine.

[21]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[22]  L. Cosmi,et al.  Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.

[23]  D. Jarrossay,et al.  Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells , 2007, Nature Immunology.

[24]  Kathleen M. Smith,et al.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis , 2006, The Journal of experimental medicine.

[25]  D. Margolis,et al.  Risk of myocardial infarction in patients with psoriasis. , 2006, JAMA.

[26]  K. Asadullah,et al.  IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis , 2006, European journal of immunology.

[27]  Y. Sung,et al.  STAT3 and NF-κB Signal Pathway Is Required for IL-23-Mediated IL-17 Production in Spontaneous Arthritis Animal Model IL-1 Receptor Antagonist-Deficient Mice1 , 2006, The Journal of Immunology.

[28]  F. Nestle,et al.  Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.

[29]  A. Gottlieb,et al.  Differential Expression of Phosphorylated NF-κB/RelA in Normal and Psoriatic Epidermis and Downregulation of NF-κB in Response to Treatment with Etanercept , 2005 .

[30]  Frank O. Nestle,et al.  Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor-α , 2004, The Journal of experimental medicine.

[31]  G. Cooper,et al.  Direct Binding and Activation of STAT Transcription Factors by the Herpesvirus saimiri Protein Tip* , 2000, The Journal of Biological Chemistry.

[32]  S. Caspar-Bauguil,et al.  Mildly oxidized low-density lipoproteins decrease early production of interleukin 2 and nuclear factor kappaB binding to DNA in activated T-lymphocytes. , 1999, The Biochemical journal.

[33]  S. K. Szabo,et al.  Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. , 1998, The Journal of investigative dermatology.

[34]  F. Pimpinelli,et al.  Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. , 1997, Journal of biological regulators and homeostatic agents.

[35]  M. Yamamura,et al.  The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. , 1993, The Journal of investigative dermatology.

[36]  N. J. Eungdamrong,et al.  Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. , 2009, The Journal of investigative dermatology.

[37]  A. Gottlieb,et al.  Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. , 2005, The Journal of investigative dermatology.